Naccarto D V, Bell C J, Lamy P P
J Am Geriatr Soc. 1979 Jan;27(1):34-7. doi: 10.1111/j.1532-5415.1979.tb01718.x.
A study was made of 73 elderly patients receiving methenamine and ascorbic acid concurrently. Each patient had an indwelling Foley catheter. Urinary pH was assessed in relation to the dosage of ascorbic acid, duration of therapy, formulation, and dosing intervals for ascorbic acid and methenamine. Statistical analysis revealed a significant increase in urinary pH when the dosage of ascorbic acid was increased. No significant relationships were found between urinary pH and the dosage forms of ascorbic acid, the salt of methenamine used, or the duration of methenamine therapy. Changes in urinary pH at different dosing intervals for ascorbic acid were found to be significant, at the 10 percent level only, for the three-times-daily dose schedule. These data raise a question as to the value of ascorbic acid for acidifying the urine of catheterized patients receiving methenamine therapy.
对73例同时接受乌洛托品和维生素C的老年患者进行了一项研究。每位患者都留置了Foley导尿管。评估了尿pH值与维生素C剂量、治疗持续时间、制剂以及维生素C和乌洛托品给药间隔的关系。统计分析显示，当维生素C剂量增加时，尿pH值显著升高。未发现尿pH值与维生素C剂型、所用乌洛托品盐或乌洛托品治疗持续时间之间存在显著关系。仅在每日三次给药方案中，发现不同维生素C给药间隔下的尿pH值变化在10%水平上具有显著性。这些数据对接受乌洛托品治疗的留置导尿管患者使用维生素C酸化尿液的价值提出了疑问。
